Decompensation of cardiovascular disease in infection SARS-CoV-2


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Patients with cardiovascular pathology have a high risk of severe disease course and death in new coronavirus infection COVlD-19. One of the key aspects of pathogenesis in such cases is disorders in the platelet link of hemostasis, which predisposes to the development of venous thrombosis and thromboembolism of the pulmonary artery. A clinical case of decompensation of cardiovascular disease in a patient with SARS-CoV-2 infection without typical clinical signs of coronavirus infection is considered.

Texto integral

Acesso é fechado

Sobre autores

Lyudmila Melnikova

Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia

Email: lumel2408@yandex.ru
MD, associate professor, professor of the Department of general medical practice and polyclinic therapy 125445, Moscow, 53 Smol'naya Str

Tatiana Lokhina

Penza Institute for Further Training of Physicians - branch of the Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia

Email: ltv-13ra@mail.ru
MD, head of the Department of therapy, cardiology, functional diagnostics and rheumatology 440060, Penza, 8А Stasova Str

Natalia Berenshtein

Penza Institute for Further Training of Physicians - branch of the Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia

Email: berenshtein2011@yandex.ru
PhD, associate professor of the Department of ultrasound diagnostics 440060, Penza, 8А Stasova Str

Bibliografia

  1. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5.
  2. Guzik T.J., Mohiddin S.A., Dimarco A. et al. COVID-19 and the cardiovascular system implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research. 2020; 116(10):1666-87. doi: 10.1093/cvr/cvaa106.
  3. Xiong T.Y., Redwood S., Prendergast B. et al. Coronaviruses and the cardiovascular system: acute and longterm implications. Eur Heart J. 2020; 0: 1-3. doi: 10/1093/eurheartj/ehaa231.
  4. Kochi A.N., Tagliari A.P., Forleo G.B. et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovascuc Electrophysiol. 2020; 31(5): 1003-08. doi.org/10.1111/jce.14479.
  5. Walls A.C., Park Y.J., Tortorici M.A. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181(2): 281-92.e6. doi: 10.1016/j.cell.2020.02.058.
  6. Коган Е.А., Березовский Ю.С., Проценко Д.Д. с соавт. Патологическая анатомия инфекции, вызванной SARS-CoV-2. Судебная медицина. 2020; 2: 8-30. doi: https://dx.doi.org/10.19048/2411-8729-2020-6-2-8-30.
  7. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020; 14(3): 247-50. doi: 10.1016/j.dsx.2020.03.013.
  8. Рекомендации ESC по диагностике и лечению острой легочной эмболии, разработанные в сотрудничестве с Европейским респираторным обществом (ERS), 2019. Российский кардиологический журнал. 2020; 8: 3848. doi: https://doi.org/10.15829/1560-4071-2020-3848.
  9. Bikdeli B., Madhavan M.V., Jimenez D. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75(23): 2950-73. doi: 10.1016/j.jacc.2020.04.031.
  10. Lew T.W., Kwek T.K., Tai D. et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003; 290(3): 374-80. doi: 10.1001/jama.290.3.374.
  11. Chong P.Y., Chui P., Ling A.E. et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med. 2004; 128(2): 195-204. doi: 10.1043/1543-2165.
  12. Анаев Э.Х., Княжеская Н.П. Коагулопатия при covid-19: фокус на антикоагулянтную терапию. Практическая пульмонология. 2020; 1: 3-13.
  13. Lippi G., Favaloro E.J. D-dimer is associated with severity of coronavirus disease 2019: A pooled analysis. Thromb Haemost. 2020; 120(5): 876-78. doi: 10.1055/s-0040-1709650.
  14. Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A metaanalysis. Clin Chim Acta. 2020; 506:145-48. doi: 10.1016/j.cca.2020.03.022.
  15. Tang N., Li D., Wang X. et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844-47. doi: 10.1111/jth.14768.
  16. Thachil J., Tang N., Gando S. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5): 1023-26. doi: 10.1111/jth.14810.
  17. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-69. doi: 10.1001/jama.2020.1585.
  18. Буланов А.Ю., Симарова И.Б., Буланова Е.Л. с соавт. Новая коронавирусная инфекция COVID-19: клиническая и прогностическая значимость оценки фибриногена плазмы. Вестник интенсивной терапии им. А.И. Салтанова. 2020; 4: 42-47. doi: https://doi.org/10.21320/1818-474X-2020-4-42-47.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2021

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies